# A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer

> **NCT00058526** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 61 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **BIOLOGICAL:** Immunotherapeutic SB719125 (Primary)

## Key facts

- **NCT ID:** NCT00058526
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03-20
- **Primary completion:** 2006-09-06
- **Final completion:** 2006-09-06
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00058526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00058526, "A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00058526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*